Q-omics provides the consensus-scored STXBP5L profile across patient tissues and cancer cell-line models. STXBP5L expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, STXBP5L is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, STXBP5L RNA expression shows 17,317 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight UVM, THCA, and PCPG as cancer lineages where STXBP5L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STXBP5L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STXBP5L survival associations across molecular data types. STXBP5L RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STXBP5L RNA expression–survival associations across cancer types. High STXBP5L expression shows unfavorable associations in BLCA, KIRP, LIHC, READ and COAD, but favorable associations in UVM. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for STXBP5L RNA expression.
This table summarizes STXBP5L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for STXBP5L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STXBP5L shows lower tumor expression in THCA, COAD, KIRC and BLCA and higher tumor expression in KICH and LUSC. The THCA box plot shows higher STXBP5L RNA expression in normal versus tumor tissue (log2 FC = −3.026, t-test p < 0.001).
This table shows molecular features associated with STXBP5L in patient tissues and cancer cell lines. In patient samples, STXBP5L shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set. In cancer cell lines, STXBP5L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LUNG_SCLC.
